Skip to main content
Fig. 1 | BMC Neurology

Fig. 1

From: Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study

Fig. 1

Patient disposition (placebo-controlled period). *Completed and withdrawn data refer to the number of patients completing or withdrawing in the placebo-controlled period. **Three patients from the eptinezumab group were excluded from the full analysis set because no post-baseline primary endpoint data were contributed. AE, adverse event

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us